CD274 and neuroendocrine carcinoma: In reaction to the modest response and clinical outcomes associated withsingle-agent anti-PD-1/PD-L1 therapy in patients with advanced PD-NEC,strategies with the intention of increasing efficacy are under investigation(Tables 4, –6).